Our earliest capture with readable facts. This is our first observation, not when the company introduced these things. These website claims are not independently verified.
All facts above belong to this capture. Unlisted fields mean we have no readable observation, not that they were absent.
How it describes itself
Similar headlines are grouped together. The quote shown is from the last capture in each group, not necessarily the exact wording throughout that period.
Seen November 2026 · 1 capture · latest observed messagingThe science of nVNS
At electroCore, we are developing non-invasive vagus nerve stimulation (nVNS) therapy for the treatment of multiple conditions in neurology and metabolic disorders.
September 2023 – September 2026 · 5 captureselectroCore | Pioneers of Tech. Stimulators of Life.
At electroCore, we are developing non-invasive vagus nerve stimulation (nVNS) therapy for the treatment of multiple conditions in neurology and metabolic disorders.
23 September 2023 · electroCore | Pioneers of Tech. Stimulators of Life.archived page
1 January 2025 · electroCore | Pioneers of Tech. Stimulators of Life.archived page
3 August 2025 · electroCore | Pioneers of Tech. Stimulators of Life.archived page
30 April 2026 · electroCore | Pioneers of Tech. Stimulators of Life.archived page
9 September 2026 · electroCore | Pioneers of Tech. Stimulators of Life.archived page
Seen January 2022 · 1 captureNow FDA Cleared
At electroCore, we are developing non-invasive vagus nerve stimulation (nVNS) therapy for the treatment of multiple conditions in neurology and metabolic disorders.
July 2018 – July 2020 · 2 capturesWhat our future holds
At electroCore, we are developing non-invasive vagus nerve stimulation (nVNS) therapy for the treatment of multiple conditions in neurology and metabolic disorders.
Seen February 2017 · 1 captureElectroCore Medical, LLC
ElectroCore’s mission is to find new and better solutions to humanity’s healthcare challenges. We have developed innovative therapies that treat or prevent